CA3213008A1 - Sars-cov-2 mpro inhibitor compounds - Google Patents
Sars-cov-2 mpro inhibitor compounds Download PDFInfo
- Publication number
- CA3213008A1 CA3213008A1 CA3213008A CA3213008A CA3213008A1 CA 3213008 A1 CA3213008 A1 CA 3213008A1 CA 3213008 A CA3213008 A CA 3213008A CA 3213008 A CA3213008 A CA 3213008A CA 3213008 A1 CA3213008 A1 CA 3213008A1
- Authority
- CA
- Canada
- Prior art keywords
- azabicyclo
- hexane
- dioxobutan
- carboxamide
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2104742.8 | 2021-04-01 | ||
| GBGB2104742.8A GB202104742D0 (en) | 2021-04-01 | 2021-04-01 | Sars-Cov-2 MPRO inhibitor compounds |
| GBGB2107026.3A GB202107026D0 (en) | 2021-05-17 | 2021-05-17 | SARS-COV-2 MPRO inhibitor compounds |
| GB2107026.3 | 2021-05-17 | ||
| PCT/GB2022/050836 WO2022208113A1 (en) | 2021-04-01 | 2022-04-01 | Sars-cov-2 mpro inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3213008A1 true CA3213008A1 (en) | 2022-10-06 |
Family
ID=81307814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3213008A Pending CA3213008A1 (en) | 2021-04-01 | 2022-04-01 | Sars-cov-2 mpro inhibitor compounds |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240217930A1 (https=) |
| EP (1) | EP4313305A1 (https=) |
| JP (1) | JP2024511881A (https=) |
| KR (1) | KR20240004275A (https=) |
| AU (1) | AU2022247287A1 (https=) |
| CA (1) | CA3213008A1 (https=) |
| WO (1) | WO2022208113A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024525589A (ja) | 2021-07-09 | 2024-07-12 | アリゴス セラピューティクス インコーポレイテッド | 抗ウイルス化合物 |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| GB202214644D0 (en) * | 2022-10-05 | 2022-11-16 | Heptares Therapeutics Ltd | Sars-cov-2 mpro inhibitors and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| CN1498224A (zh) * | 2000-07-21 | 2004-05-19 | ���鹫˾ | 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽 |
| CA3180177A1 (en) * | 2020-05-08 | 2021-11-11 | The Board Of Trustees Of The Leland Stanford Junior University | Protease inhibitors for treatment or prevention of coronavirus disease |
-
2022
- 2022-04-01 US US18/553,596 patent/US20240217930A1/en active Pending
- 2022-04-01 EP EP22716453.0A patent/EP4313305A1/en active Pending
- 2022-04-01 JP JP2023560997A patent/JP2024511881A/ja active Pending
- 2022-04-01 KR KR1020237033735A patent/KR20240004275A/ko active Pending
- 2022-04-01 AU AU2022247287A patent/AU2022247287A1/en not_active Abandoned
- 2022-04-01 CA CA3213008A patent/CA3213008A1/en active Pending
- 2022-04-01 WO PCT/GB2022/050836 patent/WO2022208113A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024511881A (ja) | 2024-03-15 |
| KR20240004275A (ko) | 2024-01-11 |
| EP4313305A1 (en) | 2024-02-07 |
| WO2022208113A1 (en) | 2022-10-06 |
| US20240217930A1 (en) | 2024-07-04 |
| AU2022247287A1 (en) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3213008A1 (en) | Sars-cov-2 mpro inhibitor compounds | |
| RU2607045C2 (ru) | Бензиламиновые производные как ингибиторы калликреина плазмы | |
| EP0813867B1 (en) | Retroviral protease inhibitors | |
| KR100296463B1 (ko) | 레트로바이러스프로테아제저해제로서유용한히드록시에틸아미노술폰아미드 | |
| EP4263502B1 (en) | Sars-cov-2 mpro inhibitor compounds | |
| EP0731088B1 (en) | Retroviral protease inhibitors | |
| JP5528113B2 (ja) | トランスグルタミナーゼ阻害剤としてのマイケル・システム | |
| EP0666842B1 (en) | Hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors | |
| BRPI0413582B1 (pt) | Compostos, composições e métodos para inibir a atividade de proteasome | |
| JPH08500824A (ja) | レトロウイルスプロテアーゼ阻害剤として有用なｎ−（アルカノイルアミノ−２−ヒドロキシプロピル）スルホンアミド | |
| US9434762B2 (en) | Macrocyclic cysteine protease inhibitors and compositions thereof | |
| ES2391813T3 (es) | Derivados aromáticos como inhibidores de la proteasa de aspartilo del VIH | |
| US12060333B2 (en) | Aminocarbamoyl compounds for the treatment of viral infections | |
| WO2017151587A1 (en) | Aza-peptide aldehydes and ketones | |
| US20230099089A1 (en) | Antiviral substances with a wide spectrum of activity | |
| US20240150396A1 (en) | Inhibitors of cysteine proteases | |
| CN117858867A (zh) | Sars-cov-2 mpro抑制剂化合物 | |
| KR0159652B1 (ko) | 항 에이즈 효과를 갖는 비가역적 인간 면역 결핍 바이러스 프로테아제 저해제 및 그의 제조방법 | |
| HK40094156B (en) | Sars-cov-2 mpro inhibitor compounds | |
| HK40094156A (en) | Sars-cov-2 mpro inhibitor compounds | |
| CN117136178A (zh) | SARS-COV-2 Mpro抑制剂化合物 | |
| EP4685151A1 (en) | Proteasome inhibitor | |
| US20230212203A1 (en) | Antiviral Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20240726 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241125 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250304 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250304 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250304 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250612 |